SEC Form 4 · accession 0001209191-17-014418
Evoke Pharma Inc · EVOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth J Widder
Director
Period of report
Feb 22, 2017
Accepted (ET)
Feb 24, 2017 · 5:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403708
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 22, 2017 | P | 418,605 | $2.90 | A | 1,472,867 | I | Directly owned by LVP III |
| Common StockF1 | Feb 22, 2017 | P | 20,930 | $2.90 | A | 73,641 | I | Directly owned by Associates |
| Common StockF1 | Feb 22, 2017 | P | 10,465 | $2.90 | A | 36,821 | I | Directly owned by Partners |
| Common StockF1 | holding | — | — | — | 5,250 | I | Directly owned by LVPMC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported securities are owned directly by each of LVPMC, LLC ("LVPMC"), LVP Life Science Ventures III, L.P. ("LVP III"), LVP III Associates, L.P. ("Associates") and LVP III Partners, L.P. ("Partners"). LVP GP III, LLC ("GP III") is the general partner of LVP III, Associates and Partners. The reporting person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.